Award details

Bifunctional thermostable DNA polymerases with dual DNA polymerase and reverse transcriptase activities for use in qRT-PCR

Reference	BB/F00687X/1
Principal Investigator / Supervisor	Professor Bernard Connolly
Co-Investigators / Co-Supervisors	Dr Richard Lewis
Institution	Newcastle University
Department	Inst for Cell and Molecular Biosciences
Funding type	Research
Value (£)	441,649
Status	Completed
Type	Research Grant
Start date	30/06/2008
End date	29/06/2011
Duration	36 months

Abstract

Reverse transcription PCR (RT-PCR), where RNA is first copied to DNA and then amplified has traditionally been used for cDNA cloning i.e. to prepare eukaryotic cDNA libraries and as a prelude to the overproduction of eukaryotic proteins. Recently, however, there has been explosive growth in RT-PCR for real time/quantitative applications to measure cellular levels of mRNA, and hence gene expression, often within the context of microarray analysis. Most usually RT-PCR requires two enzymes, a reverse-transcriptase to copy RNA to DNA and a thermostable DNA polymerase for subsequent DNA amplification, although under some conditions a single DNA polymerase can catalyse both steps. The continued growth in RT-PCR has created a large demand for simple and robust enzyme systems capable of converting a tiny quantity of RNA to large amounts of double stranded DNA. Many problems are presented by the enzymes in current use and RT-PCR remains much more challenging than normal PCR. Thus, two enzyme-systems give rise to difficulties in optimising conditions to simultaneously meet the requirements of both proteins, and inconvenient two step protocols are often required. Single enzymes systems invariably operate under sub-optimal conditions of yield and fidelity. This application seeks to produce bifunctional DNA polymerases with both reverse transcriptase and DNA polymerase activities. Compartmentalised self replication (CSR), a directed evolution method will be the principal method used, along with a novel selection strategy based on chimeric RNA-DNA primers. It is anticipated that the bifunctional polymerase will possess high thermostability, rapid amplification rates and high fidelity and, it is hoped, should make RT-PCR as simple, robust and straightforward as PCR currently carried out with thermostable bacterial and archaeal polymerases. Such an enzyme will be applicable to many real-time PCR applications, a rapidly growing market currently worth ~ $1000 million

Summary

Reverse transcription PCR (RT-PCR) is a protocol that involves copying RNA, most commonly messenger RNA (mRNA), to DNA and then amplifying the DNA produced. In this way a tiny amount of RNA can be converted to large quantities of DNA, with retention of the sequence information encoded in the RNA. In the past RT-PCR has mainly been used to prepare cDNA libraries from eukaryotes such as humans and yeast. A cDNA library is a snapshot of every mRNA present in a cell or tissue at a particular instance and can give valuable insights about the status and functioning of a cell. With eukaryotes it is also necessary to produce cDNA in order to use recombinant DNA techniques to obtain large quantities of proteins, for example, human insulin, growth hormones and blood clotting factors, used for disease treatment. More recently RT-PCR has undergone enormous expansion with the development of quantitative or real time PCR (denoted here, qRT-PCR), a technology that allows the accurate measurement of the amount of any mRNA present in a cell/tissue. qRT-PCR is amenable to a high degree of automation and can be used to simultaneously quantify a large number of mRNA levels. The technique is of immense application in fundamental research for example to determine at what levels mRNAs are expressed in particular cells and organs, how and why distinct cell types differ in their mRNA levels and how these levels respond to differing conditions such as age, nutritional status and stress levels. qRT-PCR is of high medicinal significance and can determine mRNA levels in cancerous tumours or tissues subject to autoimmune disease. The method can assess how cells respond to bacterial and viral infections or how drugs influence the expression of particular mRNAs. Thus qRT-PCR is used both to monitor disease progression and to suggest therapeutic intervention. Normally RT-PCR requires two enzymes, reverse-transcriptase to copy the RNA to DNA and DNA polymerase to amplify the DNA produced. However, the use of two enzymes often gives rise to problems, especially in automated high throughput qRT-PCR. It is frequently difficult to optimise conditions to simultaneously meet the requirements of both enzymes, and inconvenient two step protocols are often required. Furthermore the reverse transcriptase often gives low yields of product and is intrinsically error prone, leading to loss of genetic information. There are some single enzyme systems for RT-PCR, typically using a DNA polymerase under conditions were it is able to copy RNA to DNA. Such conditions are invariably sub-optimal both in regards to final product yield and in the fidelity with which genetic information is transmitted from the starting RNA to the amplified DNA product. The aim of this grant is to produce a single bifunctional enzyme with both reverse transcriptase and DNA polymerase activities. The starting enzyme will be a thermostable DNA polymerase from an archaeon (Pyrococcus furiosus), capable of rapid and accurate amplification of DNA. A directed evolution method will be used to endow these enzymes with an additional reverse transcriptase activity. The evolution strategy randomises amino acids in the starting enzymes and then uses a protocol that specifically selects for novel variants with both DNA polymerase and reverse transcriptase activities. It is anticipated that the bifunctional polymerase produced will possess high thermostability, rapid amplification rates and high fidelity and, it is hoped, should make RT-PCR, an especially qRT-PCR, simple, robust and straightforward. Such an enzyme will be applicable to in the many, and expanding, real-time PCR applications described above. It should be noted that the real time PCR market is currently worth ~ $1000 million, and growing rapidly.

Committee	Closed Committee - Engineering & Biological Systems (EBS)
Research Topics	Microbiology, Technology and Methods Development
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search